Valuation: Allergy Therapeutics plc

Market Cap 424M 568M 497M 459M 805M 54.26B 819M 5.49B 2.15B 26.64B 2.13B 2.09B 92.29B P/E 2026 *
-8.38x
P/E 2027 * -
Enterprise Value 462M 619M 542M 499M 877M 59.09B 892M 5.98B 2.34B 29.02B 2.32B 2.27B 101B EV / Sales 2026 *
7.33x
EV / Sales 2027 * -
Free-Float
11.51%
Yield 2026 *
-
Yield 2027 * -
1 week+3.72%
Current month-5.63%
1 month-20.99%
3 months-36.79%
6 months-43.70%
Current year-39.09%
1 week 6
Extreme 6
7
1 month 6
Extreme 6
8.5
Current year 6
Extreme 6
12.1
1 year 6
Extreme 6
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 2009-08-31
Director of Finance/CFO - 2023-08-10
Corporate Officer/Principal 62 2026-01-28
Director TitleAgeSince
Director/Board Member 62 2009-08-31
Chairman 75 2011-01-03
Director/Board Member 69 2017-06-05
Date Insider Type Main position Quantity % Market Cap.
06-12Free

Chief Financial Officer

2,300,000 0.0363%
03-11
ZQ Capital Ltd.
SellCompany 14,742,000 0.2400%
03-11
ZQ Capital Ltd.
SellCompany 3,684,000 0.0600%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.72%-16.25%+354.24% 567M
+0.38%+1.79%+20.52%-5.32% 67.44B
+0.52%-5.52%+46.80%+218.71% 53.98B
-2.79%+32.50%+32.50%+32.50% 41.77B
+0.99%+6.05%-48.96%-52.97% 41.15B
-0.08%-7.47%+50.33%-28.98% 29.58B
+3.81%-4.16%+133.12%-37.90% 29.28B
+1.00%+1.20%+72.09%+91.08% 23.43B
+0.17%+8.48%+4.86%+185.45% 19.11B
+1.14%-0.17%+68.83%+134.48% 16.82B
Average +0.50%+1.80%+36.38%+89.13% 32.31B
Weighted average by Cap. +0.39%+1.06%+35.81%+51.99%

Financials

2026 *2027 *
Net sales 63M 84.4M 73.84M 68.09M 120M 8.06B 122M 815M 320M 3.96B 317M 310M 13.7B -
Net income -49.3M -66.05M -57.78M -53.28M -93.57M -6.3B -95.14M -638M -250M -3.1B -248M -243M -10.72B -
Net Debt 37.8M 50.64M 44.3M 40.85M 71.75M 4.83B 72.95M 489M 192M 2.37B 190M 186M 8.22B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
26-07-09 GBX 6.700 0.00% 241,411
26-07-08 GBX 6.700 +1.52% 51,314
26-07-07 GBX 6.600 -3.23% 152,700
26-07-06 GBX 6.820 +3.33% 116,963
26-07-03 GBX 6.600 +2.17% 233,084
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0670GBP
Average target price
0.1300GBP
Spread / Average Target
+94.03%

Annual profits - Rate of surprise